In summary, these findings demonstrate that TLR9 signaling may play a role in CLL drug resistance in the LN microenvironment by promoting protein translation, thereby increasing susceptibility of CLL cells to CD40-mediated pro-survival signaling. This evidence concerns the gene TLR9 and B-cell chronic lymphocytic leukemia.